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INTRODUCTION:  Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates 
pemetrexed cytotoxicity in argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural 
mesothelioma (MPM). We conducted a phase 1 dose-expansion study at the recommended 
phase 2 dose (RP2D) of ADI-PEG 20 with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis), 
to further evaluate arginine-lowering therapy in ASS1-deficient MPM and explore mechanisms 
of resistance.   
 
METHODS: Thirty-two chemonaïve patients with ASS1-deficient MPM (11 epithelioid;10 
biphasic;11 sarcomatoid) received weekly intramuscular pegargiminase (36 mg/m2) with Pem 
(500 mg/m2) and Cis (75 mg/m2) intravenously, every three weeks (six cycles maximum). 
Maintenance pegargiminase was permitted until disease progression or withdrawal. Safety, 
pharmacodynamics, immunogenicity, and efficacy were determined. Biopsies were performed in 
progressing patients to explore mechanisms of resistance to pegargiminase. 
 
RESULTS: Treatment was well-tolerated. Most adverse events (AEs) were Grade 1/2, while 
four non-hematologic Grade 3/4 AEs related to pegargiminase, were reversible. Plasma 
arginine decreased while citrulline increased; this was maintained by 18 weeks of ADIPemCis 
therapy. The disease control rate in thirty-one evaluable patients was 93.5% (n=29/31; 95% CI 
78.6% - 99.2%), with a partial response rate of 35.5 % (n=11/31; 95% CI 19.2% - 54.6%). The 
median progression-free and overall survivals were 5.6 (95% CI, 4.0 to 6.0) and 10.1 (95% CI, 
6.1 to 11.1) months, respectively. Progression biopsies on pegargiminase revealed a 
statistically significant influx of macrophages (n=6; p=0.0255) and patchy tumoral ASS1 re-









inducible gene – and the formation of CD3-positive T lymphocyte aggregates on disease 
progression (n=2/5).  
 
CONCLUSIONS: The dose-expansion of ADIPemCis confirmed high clinical activity and good 
tolerability in ASS1-deficient poor-prognosis mesothelioma, underpinning an ongoing phase 3 
study (clinicaltrials.gov NCT02709512). Notably, resistance to pegargiminase correlated 
significantly with macrophage recruitment and – along with the tumor immune microenvironment 
– warrants further study to optimize arginine deprivation for the treatment of mesothelioma. 
 
 










Malignant pleural mesothelioma (MPM) is predominantly an asbestos-driven thoracic tumor 
notable for its chemoresistance and poor prognosis. Median survivals range from 3.5 and 6.6 
months for the non-epithelioid, sarcomatoid and biphasic variants, respectively, and up to 18 
months for the epithelioid subtype.1,2 No new front-line therapies for mesothelioma have been 
licensed since the antifolate pemetrexed with cisplatin in 2004.3 
In preclinical studies we identified arginine depletion as a rational antimetabolite strategy 
that targets mesothelioma cells displaying epigenetic inactivation of the urea cycle enzyme, 
argininosuccinate synthetase 1 (ASS1).4  Arginine deprivation impacts multiple biosynthetic 
pathways including proteins, polyamines, nucleotides, and nitric oxide, emphasizing an 
essential role for the amino acid in the growth or auxotrophy of mesothelioma and other 
cancers.5-7  Consequently, bacterial-derived pegylated arginine deiminase (ADI-PEG 20, ADI or 
pegargiminase) or bioengineered forms of human arginase are currently in development for 
patients with a range of advanced malignancies.8-10   
Clinically, pegargiminase, which degrades arginine into citrulline and ammonia, improved 
progression-free survival in patients with ASS1-deficient MPM in the ADAM study, representing 
the first biomarker-driven randomized trial of arginine deprivation versus best-supportive care in 
cancer.11 Moreover, ASS1 was prognostic with ASS1-deficient disease conferring a worse 
survival compared with ASS1-proficient disease, consistent with data linking dysregulation of 
urea cycle enzymes to accelerated tumorigenesis.5,11 Additionally, when ADI-PEG 20 was 
combined with pemetrexed and cisplatin chemotherapy (ADIPemCis) in the phase I dose-
escalation TRAP (Tumors Requiring Arginine to Assess ADI-PEG 20, Pemetrexed and cisplatin) 
study a 100% disease control (78% partial response) rate was observed in nine patients with 
thoracic cancers (lung adenocarcinoma and MPM), including four of five patients with non-








reciprocal increase in citrulline, patients progressed on ADIPemCis therapy, thereby implicating 
tumoral, rather than drug-innate, mechanisms of resistance to arginine deprivation. 
First, re-expression of ASS1, and thus the recycling of citrulline to arginine, following 
long-term culture of tumor cell lines including MPM cells in ADI-PEG 20, has been identified as 
a viable resistance mechanism with confirmatory studies in patients with melanoma.13-15 
Secondly, autophagy (the degradation and recycling of cellular components) is known to protect 
ASS1-negative MPM cells from arginine depletion.16 Thirdly, the tumor microenvironment may 
also mediate cancer cell resistance to arginine withdrawal however this has not been addressed 
specifically in the context of pegargiminase. Tumor-associated macrophages (TAMs), in 
particular, constitute up to 30% of the total cell population of mesothelioma and play a key role 
in asbestos-mediated tumorigenesis.17-20 As such, TAMs might also play a role in resistance to 
arginine deprivation therapy. 
Here, we treated a dose-expansion cohort of thirty-two patients with ASS1-deficient MPM 
at the recommended phase 2 dose (RP2D) of ADI-PEG 20 (36mg/m2) in combination with 
standard doses of pemetrexed and cisplatin. The main aims of this phase 1 dose-expansion 
study were to define further the safety and preliminary activity of the ADIPemCis triplet in 
patients with MPM, and to elucidate mechanisms of resistance to arginine deprivation by 




















Patients were aged 18 years or over, chemonaive with histologically proven ASS1-deficient  
advanced MPM (see Beddowes et al for methods).12 Additional eligibility included an ECOG 
performance status 0 or 1, no major co-morbidities, a minimum expected survival of 3 months, 
and measurable disease by modified Response Evaluation Criteria in Solid Tumors criteria 
(RECIST) for MPM.  Exclusion criteria included recent major surgery, history of another active 
primary cancer, and prior therapy with pegargiminase. All patients signed written informed 
consent. 
 
Study Design and Treatment 
 
This dose-expansion multicentre phase 1 study evaluated the RP2D of 36 mg/m
2 weekly 
intramuscular ADI-PEG 20 plus three-weekly 75 mg/m
2 cisplatin and 500 mg/m
2
 pemetrexed 
derived from the previous dose-escalation TRAP study.11 Standard premedication was 
administered, including oral dexamethasone, daily folic acid, and 1000µg intramuscular (IM) 
hydroxycobalamin every nine weeks. The initial dose of IM ADI-PEG 20 was administered 48 
hours before the first dose of cytotoxic drugs. Patients received up to 6 cycles (18 weeks) of 
ADIPemCis chemotherapy and could continue on maintenance pegargiminase until disease 
progression or withdrawal. Blood samples were taken at baseline, during ADIPemCis 
chemotherapy, and on disease progression or withdrawal from the study. Tumor biopsies were 
required at baseline and were optional at disease progression.  
The primary objective of the dose-expansion study was to determine the safety and 









deficient MPM. Secondary objectives included measuring pharmacodynamics, immunogenicity, 
and exploration of resistance mechanisms to pegargiminase.  
 
Safety 
Evaluation of safety was based on the National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.03, vital signs, physical examination, ECGs, and 
laboratory blood analyses.  
 
Pharmacodynamic and Efficacy Evaluations 
Blood samples were analyzed by Polaris Pharmaceuticals, Inc., (San Diego, California, USA) 
for arginine and citrulline levels and anti-ADI-PEG 20 antibody titres, as described 
previously.11,12 Efficacy was assessed by computed tomography imaging using modified 
RECIST every 6 weeks while on ADIPemCis and then every 2 months on maintenance 
pegargiminase. 
 
Patient tumor Immunohistochemistry (IHC) 
Tumor biopsies were assessed for ASS1 expression using mAb 195-21-1 from Polaris 
Pharmaceuticals, Inc., San Diego, California, USA. Infiltrating CD68pos macrophages were 
identified using a murine anti-human antibody (KP-1) and quantified as a percentage of the 
number of malignant cells, taking an average from five high-power fields at 400x magnification. 
PD-L1 (Cell Signalling E1L3N and Ventana-Roche SP-263 antibodies) and CD3 (Ventana-
Roche 2GV6 antibody) expression was performed subsequent to the CD68 staining using 
residual tissue. PD-L1 was scored as a percentage of positive tumour cells and CD3 











No formal sample size calculation was made for the dose-expansion TRAP study in patients 
with MPM, which aimed to recruit up to 30 patients as per protocol. AEs were collated, and 
response rates, PFS and OS characterized according to MPM subtype. Patients’ tumour 
biopsies were analyzed using a paired t-test in GraphPad Prism version 8.3.1. A p-value of 




The clinical protocol (ClinicalTrials.gov identifier NCT02029690) was approved by Leeds East 














Patient enrolment into the dose-expansion study began in February 2015 and was completed in 
May 2016. Ninety-three patients were screened to recruit thirty-two patients with ASS1-deficient 
MPM treated with ADIPemCis: eleven with epithelioid, ten with biphasic, and eleven with the 
sarcomatoid subtype (Fig. 1). The protocol amendment for the dose-expansion cohort specified 
the enrollment of thirty patients at the RP2D; one patient was deemed ineligible and replaced 
due to occult malignant melena and an additional patient consented as the study recruitment 
was closing. All subjects were included for the safety analysis and thirty-one for the efficacy 
analysis (Table 1).  
 
Safety 
Consistent with the prior dose-escalation study, ADIPemCis treatment was well-tolerated 
(Supplementary Tables 1 and 2). Adverse events were reported in 24/32 (75%) patients, the 
majority of which were related to cisplatin and/or pemetrexed, namely 22/32 (68.8%), and to 
pegargiminase in 12/32 (37.5%) patients. The majority were Grade 1 or 2  (116/137 or 84.7%) 
particularly nausea and vomiting and decreased blood counts, with the remainder Grade 3 or 4 
only (21/137 or 15.3%). There were four non-haematologic Grade 3 or 4 adverse events related 
to pegargiminase: increased alkaline phosphatase, hyperuricaemia, skin rash and posterior 
reversible encephalopathy syndrome. The latter was unexpected and occurred in a patient with 
a sarcomatoid mesothelioma presenting with agitation and characteristic MRI features during 
maintenance pegargiminase. He recovered completely following anxiolytics, steroids and 










Pegargiminase decreased plasma arginine with a reciprocal increase in plasma citrulline levels 
in patients (Fig. 2A). As reported in the dose-escalation cohort, plasma levels of the amino acids 
remained differentially altered compared with pre-treatment levels by 18 weeks, despite a 
concomitant increase in anti-ADI-PEG 20 antibodies (Fig. 2B).  
 
Efficacy  
ADIPemCis treatment induced a high disease control rate of 93.5% (n=29/31; 95% CI 78.6% - 
99.2%), with a partial response rate of 35.5 % (n=11/31; 95% CI 19.2% - 54.6%) in a cohort of 
patients enriched by ASS1 loss for non-epithelioid MPM (Fig. 2C, D). The median progression-
free survival (PFS) and overall survival (OS) were 5.6  (95% CI, 4.0 to 6.0) and 10.1 (95% CI, 
6.1 to 11.1) months, respectively (Fig. 3A, B). Subsequently, 11/31 (35.5%) patients received 
anti-PD1 therapy with pembrolizumab achieving stable disease in one patient (9.1%), while nine 
patients had progressive disease  (81.8%) and one patient was non-evaluable (9.1%). PD-L1 
expression prior to treatment was available in 9/11 patients ranging from 0% (n=4) to 1-30% (n-
5). Due to rapidly progressive disease a minority of patients received second-line and 
subsequent therapies (vinorelbine and/or gemcitabine).  
 
Exploratory Tumor Biopsies 
To understand drug resistance six patients on pegargiminase therapy consented to a tumor 
rebiopsy at progression allowing a comparison with the pre-treatment biopsies.  ASS1 levels 
increased in a subpopulation of MPM cells in two of six patients with epithelioid and 









increase of CD68pos ASS1pos macrophages at disease progression in ASS1neg tumor areas, 
which included four patients receiving maintenance pegargiminase for up to 18 months 
(p=0.0255; n=6; Fig. 4B, C). Due to patchy ASS1 tumoral re-expression seen in two patients 
only we were unable to quantify the amount of macrophage infiltration specifically in ASS1pos 
tumor areas. We also noted an increase in tumoral PD-L1 expression and clustering of CD3pos T 
lymphocytes within MPM tumor cell islands in two of five patients with available tissue for IHC 
(Fig. 5). In the remaining three patients we detected variable effects on PD-L1 expression 














In this ASS1 biomarker-led study we observed good tolerability and a high rate of disease 
control in patients enriched with poor-prognosis MPM treated with the RP2D of ADIPemCis, 
expanding on the preliminary signal in the dose-escalation trial. Nonetheless, tumor progression 
on pegargiminase was universal, and instead of widespread ASS1 tumoral re-expression, 
correlated significantly with macrophage infiltration on rebiopsy, pointing to a stromal-mediated 
resistance pathway that may be leveraged to optimise arginine-depleting cancer therapeutics. 
We also describe induction of tumoral PD-L1 expression and modulation of T lymphocytes, 
which segues into the developing area of mesothelioma immunotherapy.  
 Toxicities were mostly Grade 1 or 2 nausea and vomiting, haematologic and injection 
skin reactions, while grade 3 or 4 events were manageable and reversible. There was only one 
serious Grade 3 toxicity attributed to pegargiminase maintenance therapy, namely posterior 
reversible encephalopathy syndrome, a known complication of several bio-chemotherapies, 
including bevacizumab and the enzyme therapeutic, asparaginase, but described here for the 
first time with arginine deprivation.21  
The median OS and PFS of 10.1 and 5.6 months, respectively, are encouraging in a 
patient cohort enriched for poor-prognosis ASS1-deficient disease. Biomarker screening 
selected 2-3 times as many patients with non-epithelioid compared to epithelioid disease, 
consistent with prior datasets for ASS1 loss in MPM, and accounting for the unusually high rate 
of patients enrolled with non-epithelioid disease (65.6%).4,12,22 The median OS for epithelioid 
disease was 11.1 months and lower than that reported in recent phase 3 studies with median 
OS of 16.1 months for patients with predominantly epithelioid disease (81-97%) in the standard 
chemotherapy groups (LUME-meso and MAPS trials).23,24 Moreover, twice as many patients 









indicating that the latter subgroup is at the aggressive end of the spectrum, and concurring with 
poor-prognosis epithelioid disease defined by nuclear grading and p16 loss on multivariate 
analysis.25,26 
Notably, the 8.2 month median OS for non-epithelioid disease compares favourably with 
the recent SWOG S0905 trial reporting a median OS of 6.3 months for PemCis plus placebo or 
6.5 months for PemCis plus the VEGFR antagonist, cediranib (n=23; non-epithelioid).27 
Additionally, we observed a doubling of the median survival (6.5 versus 3.5 months), and a 3-
fold increase in survival at 12 months (30% vs 10%), compared to historical controls for 
sarcomatoid mesothelioma.1,26 Although response assessment in mesothelioma is challenging, 
and reported infrequently in trials for non-epithelioid disease, the 93.5% disease control rate is 
encouraging and consistent with the earlier dose-escalation study.12 Collectively, these data 
benchmarked the design of the ATOMIC-meso study, which transitioned from phase 2 to phase 
3 earlier this year after successful recruitment of 176 patients with non-epithelioid 
mesothelioma; a further 210 patients are being enrolled to report on the primary endpoint of OS 
(ClinicalTrials.gov identifier NCT02709512).   
 A key exploratory aim of the dose-expansion study was to understand resistance to ADI-
PEG20 based therapy by sampling patients’ tumors on progression. Six patients consented to 
repeat biopsies which were incorporated into patient management, most commonly for control 
of a recurrent pleural effusion. Due to limited baseline tissue, we analyzed ASS1 status followed 
by CD68 expression on macrophages, and lastly PD-L1 expression and CD3 expression on 
lymphocytes. Patchy induction of tumoral ASS1 was identified in two patients, supporting a 
limited role for ASS1 re-expression as a mechanism of resistance to pegargiminase as 
identified in long-term MPM cell line culture under ADI-PEG 20.13 This contrasted with a robust 
and statistically significant influx of CD68pos ASS1pos macrophages in ASS1-deficient tumoral 









under proinflammatory cytokine control.28 Moreover, arginine metabolism is a critical component 
of macrophage function, including nitric oxide synthesis for pathogen recognition and polyamine 
synthesis for wound healing.29 Interestingly, we also observed an influx of CD68pos ASS1pos 
macrophages in ASS1-deficient tumoral regions in two rebiopsied patients in a separate 
expansion study of ADIPemCis in patients with NSCLC; or, p=0.0079 for the entire thoracic 
patient cohort of ADIPemCis (Supplementary Figure 2).30  Separately, we have identified a 
novel mechanism whereby ADI-PEG 20 induces several chemoattractant proinflammatory 
cytokines from MPM cells triggering resistance to arginine deprivation via macrophage-derived 
argininosuccinate, the immediate precursor for arginine synthesis.†  
 Our analysis of resistance was limited by the availability of patient tissue, especially the 
polarisation of the infiltrating CD68pos ASS1pos macrophages (i.e. M1 and M2 macrophage 
subtypes) and the potential role of autophagy which will require further study.31,32 Indeed, 
autophagy was inferred in a separate expansion cohort study of ADIPemCis in glioblastoma 
multiforme with a patient exhibiting prolonged remission on maintenance ADI-PEG 20 with 
quinine sulphate, an antimalarial autophagy inhibitor, and on a background of durable arginine 
depletion (20.8 months).33 Indeed, autophagy as a contributory resistance mechanism has been 
described preclinically in various cancer cell lines including MPM cells, and is similarly 
abrogated with chloroquine.16,34,35 Finally, pharmacologic resistance due to neutralising 
antibodies to ADI-PEG 20 cannot be excluded entirely, as arginine levels, while persistently low 
compared to pre-treatment levels, increased at the end of the 18 week sampling period (with 
reciprocal changes in citrulline). Nonetheless, the pharmacodynamic changes were durable in 
the dose-escalation ADIPemCis study, which reported a higher median OS of 13.9 months in 
patients with thoracic cancers; these inter-study differences may be explained in part by a 
variation in the amount of blood sampling performed at each timepoint due to earlier subject 
                                                             









withdrawal in the current study (Supplementary Table 4).12 It is also significant that blood draws 
were performed weekly and just prior to ADI-PEG 20 dosing, reflecting static rather than 
dynamic changes in amino acid levels. 
 The limited analysis of tumoral PD-L1 expression and CD3 lymphocytes at progression in 
the remaining five biopsies was insufficient to draw firm conclusions. However, the upregulation 
of PD-L1 and CD3 lymphocytes in two of the five patients on rebiopsy is consistent with earlier 
preclinical work of ADI-PEG20 inducing PD-L1 in tumor cell lines and T cell infiltration in 
syngeneic tumor mouse models.36 Recently, a phase 1 study of pegargiminase and 
pembrolizumab in solid tumors completed accrual with on-treatment biopsies that evaluate the 
effects of pegargiminase specifically on T cell markers in the tumor microenvironment prior to 
PD-1 blockade (clinicaltrials.gov identifier NCT03254732).37 Although a third of patients 
received pembrolizumab on progression (6/11 epithelioid and 5/11 non-epithelioid), the disease 
control rate of 11.1% (n=1/11; biphasic disease) was disappointing and lower than that reported 
in larger patient studies of PD-1/PD-L1 blockade in mesothelioma (47%-72%).38-41 However, 
four of the pembrolizumab-treated patients expressed PD-L1 <1% (n=4/9 or 44.4), which is 
known to correlate with lower responses to PD-1 blockade compared to >1% PD-L1 MPM 
expression (Supplementary Table 5).41 Furthermore, the influx of tumor-associated 
macrophages reported above may have contributed potentially to a more immunosuppressive 
environment constraining PD1-based immune checkpoint therapy.42  
Clearly, further dissection of the complex effects of arginine deprivation on the 
mesothelioma microenvironment will be needed to understand the role of ADI-PEG20 in the 
context of mesothelioma immunotherapy.43-45 Moreover, studies in urea cycle dysregulated 
cancers suggest that biomarker analysis will be of increasing importance in guiding prognosis 
and therapeutic response to arginine-based therapeutics.46 We propose that the macrophage 









metabolite therapy for mesothelioma and other treatment-resistant cancers. Indeed, several 
approaches are under clinical evaluation including, CSF-1R, CXCR2, CD47 (‘don’t eat me’) and 
PD-1 antagonists, to retarget TAMs for tumor cell killing.47-52 
In summary, ADIPemCis is safe and active in an expansion cohort of patients with 
aggressive ASS1-deficient MPM and a phase 3 trial is underway. Our data also provide novel 
insights into resistance pathways to arginine deprivation, going beyond tumoral ASS1 re-
expression, namely macrophage trafficking. Validation of this innate-immunometabolic 
relationship, by targeting macrophages alongside tumor cells with pegargiminase therapy, has 
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Figure 1. CONSORT diagram 
Figure 2. Pharmacodynamics and Response (A) Pharmacodynamics of arginine and 
citrulline in patients treated with ADIPemCis. Serum [arginine] and [citrulline] are shown by 
week of treatment (means ± SEM). (B) Serum levels of anti-ADI-PEG 20 antibodies in all 
patients by week of ADIPemCis (Mean ± SEM); Ab, Antibody. (C) Waterfall plot of response by 
modified RECIST to ADIPemCis. (D) Spider plots showing response duration to ADIPemCis.  
Figure 3. Survival outcomes (A) Progression-free survival by MPM histological subtype. (B) 
Kaplan-Meier survival estimates by MPM histological subtype. 
Figure 4. Baseline and progression biopsies analyzed for ASS1 and CD68 (A) Tumoral 
ASS1 re-expression at progression noted in two patients (200x magnification; epithelioid and 
sarcomatoid). (B)  Increase in CD68pos macrophages at disease progression in ASS1-deficient 
tumoral regions (n=6; p=0.0255; paired t-test); 2 epithelioid, 1 sarcomatoid and 3 biphasic 
tumors (N.B. one epithelioid tumor was reclassified as biphasic on surgical rebiopsy). (C) 
Representative serial sections of epithelioid, biphasic and sarcomatoid MPM at baseline and 
progression stained for  ASS1 and CD68, showing the increase in ASS1posCD68pos 
macrophages at progression (200x magnification).  
Figure 5. Baseline and progression biopsies analyzed for PD-L1 and CD3 Modulation of 
PD-L1 expression and CD3pos lymphocytes in two patients at progression (200x magnification; 
epithelioid and biphasic). PD-L1 increased from 10 to 30% (in epithelioid disease) and 0 to 5% 
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Table 1. Demographics  
Characteristic  Epithelioid (n=11) Non-Epithelioid (n=21) 
Biphasic (n=10) Sarcomatoid 
(n=11)* 
Age, median (range), 
y 
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10 
Disease Stage# 1A (n=1); 1B (n=4) 












Time on study 
treatment, median 
(range), months 
4.6 (0.5-7.0) 6.1 (1.9-18.0) 4.1 (1.2-5.9) 









  Screening for Eligibility = 93 
• Epithelioid = 52 
• Biphasic = 17 
• Sarcomatoid = 18 
• Unknown = 6 
Enrollment (ASS1 Negative) = 32 
• Epithelioid = 11 (21% screened) 
• Biphasic = 10 (59% screened) 
• Sarcomatoid = 11 (61% screened) 
 
All patients included for AEs 
31 patients included for Efficacy Analysis 
(1 patient with sarcomatoid MPM replaced due 
to occult malignant small bowel hemorrhage) 
 
Screening Failure = 61 
• ASS1 Expression Positive = 46 
o Epithelioid = 35 
o Biphasic = 5 
o Sarcomatoid = 3 
o Unknown = 3 
• ASS1 Expression Negative but Deteriorating 
Performance Status =12  
(5 Epithelioid/2 Biphasic/4 SARC/1 Unknown) 
• ASS1 and subtype unknown = 2 
• ASS1 unknown (Epithelioid) = 1 
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